Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of the stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $35.51, for a total transaction of $177,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, December 12th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $29.94, for a total transaction of $149,700.00.
  • On Tuesday, November 7th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $31.47, for a total transaction of $157,350.00.

Shares of Genomic Health, Inc. (NASDAQ:GHDX) traded down $0.07 during trading on Wednesday, hitting $35.42. 105,318 shares of the stock were exchanged, compared to its average volume of 214,865. Genomic Health, Inc. has a 52-week low of $26.37 and a 52-week high of $37.50. The stock has a market capitalization of $1,230.00, a P/E ratio of -272.46 and a beta of 0.65.

GHDX has been the subject of several research reports. Canaccord Genuity restated a “buy” rating and set a $35.00 price target on shares of Genomic Health in a research report on Wednesday, September 27th. BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. ValuEngine upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Jefferies Group restated a “hold” rating and set a $33.00 price target on shares of Genomic Health in a research report on Thursday, September 14th. Finally, Zacks Investment Research upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $31.71.

Several institutional investors have recently made changes to their positions in GHDX. Cubist Systematic Strategies LLC purchased a new stake in shares of Genomic Health in the third quarter worth about $138,000. SG Americas Securities LLC lifted its holdings in shares of Genomic Health by 37.8% in the second quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after buying an additional 1,679 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Genomic Health by 11.4% in the second quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock worth $226,000 after buying an additional 710 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Genomic Health in the third quarter worth about $227,000. Finally, Parametric Portfolio Associates LLC lifted its holdings in shares of Genomic Health by 5.8% in the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after buying an additional 441 shares in the last quarter. 89.67% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/10/g-bradley-cole-sells-5000-shares-of-genomic-health-inc-ghdx-stock.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.